United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Takes $12.95 Million Position in United Therapeutics Corporation $UTHR

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 4th quarter, Holdings Channel reports. The firm purchased 26,583 shares of the biotechnology company’s stock, valued at approximately $12,953,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Darwin Global Management Ltd. acquired a new position in United Therapeutics during the third quarter worth approximately $317,617,000. Baillie Gifford & Co. acquired a new position in United Therapeutics during the fourth quarter worth approximately $157,390,000. UBS Group AG increased its position in United Therapeutics by 45.3% during the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after purchasing an additional 70,445 shares during the last quarter. Soleus Capital Management L.P. increased its position in United Therapeutics by 35.0% during the second quarter. Soleus Capital Management L.P. now owns 209,794 shares of the biotechnology company’s stock worth $60,284,000 after purchasing an additional 54,400 shares during the last quarter. Finally, Legal & General Group Plc increased its position in United Therapeutics by 0.6% during the third quarter. Legal & General Group Plc now owns 199,656 shares of the biotechnology company’s stock worth $83,698,000 after purchasing an additional 1,137 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $562.82, for a total value of $4,671,406.00. Following the sale, the executive vice president owned 45,172 shares in the company, valued at approximately $25,423,705.04. This trade represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $575.40, for a total transaction of $5,466,300.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at $23,311,180.20. The trade was a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 591,473 shares of company stock worth $331,434,344. 8.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several research analyst reports. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Raymond James Financial started coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Royal Bank Of Canada decreased their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Bank of America raised their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Finally, Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $619.42.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics said it will present at the Jefferies Global Healthcare Conference, keeping the company visible to investors and highlighting ongoing engagement with the healthcare investing community. Article Title
• Positive Sentiment: The company also shared updates on its PHINDER screening study and its xenokidney/EXTEND trial, which could support the long-term growth story if the clinical programs continue to progress. Article Title Article Title
• Neutral Sentiment: The stock remains supported by a generally constructive analyst backdrop, with several firms maintaining buy or outperform ratings and some raising price targets, which can help offset near-term concerns.
• Neutral Sentiment: Short-interest data showed no meaningful change in available reported shares, so this does not appear to be a major trading catalyst.
• Negative Sentiment: CEO Martine Rothblatt sold additional United Therapeutics shares, following another recent sale, and CFO James Edgemond also sold stock. Multiple insider sales can weigh on investor sentiment, especially after the company’s recent earnings miss. Article Title Article Title
• Negative Sentiment: United Therapeutics recently reported quarterly EPS and revenue below expectations, which remains an overhang on the shares despite the company’s strong profitability.

United Therapeutics Stock Performance

United Therapeutics stock opened at $562.09 on Friday. The firm has a market capitalization of $23.86 billion, a P/E ratio of 20.75, a P/E/G ratio of 1.84 and a beta of 0.60. The company has a 50-day simple moving average of $565.98 and a 200-day simple moving average of $515.55. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter last year, the company posted $6.63 EPS. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 27.07 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.